49 completed, 12 unknown, 4 not yet recruiting, 4 withdrawn. 76 Phase 2, 12 Phase 1, 7 Phase 3.
Follow Gels: new trials by email Literature Review of Gels trials Research Report on Gels
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Controlled Study, Performed to Evaluate the Safety and Efficacy of EscharEx and Its Placebo (Gel Vehicle) Compared to Non-surgical Standard of Care in Participants With Venous Leg Ulcers (VLU) EscharEx (EX-03), Placebo (Gel vehicle), Non-surgical standard of care (NSSOC) - Venus Leg Ulcers | Phase 2 | Not yet recruiting | MediWound Ltd | 45 | 2027-01-10 | 2026-10-16 |
| Phase 2 Efficacy and Safety of PP405 in Adult Females With Androgenetic Alopecia PP405 0.05% Topical Gel, Vehicle Topical Gel - Androgenetic Alopecia | Phase 2 | Not yet recruiting | Pelage Pharmaceuticals, Inc. | 200 | 2026-11-01 | 2026-10-30 |
| Phase 2/3 Efficacy and Safety of PP405 in Adult Males PP405 0.05% Topical Gel, Vehicle Topical Gel - Androgenetic Alopecia | Phase 2 / Phase 3 | Recruiting | Pelage Pharmaceuticals, Inc. | 600 | 2026-09-21 | 2026-10-28 |
| An Open Label, Single Treatment, Single Arm, Multiple Dose Phase-2 Study to Evaluate the Pharmacokinetics, Safety, and Clinical Performance of EscharEx (EX-03) in Participants With Venous Leg Ulcers EX-03 - Venous Leg Ulcer (VLU) | Phase 2 | Not yet recruiting | MediWound Ltd | 20 | 2026-08-01 | 2026-07-09 |
| Topical 5% Spironolactone Gel Versus 0.1% Adapalene Gel for Acne Vulgaris: A Randomized Split-Face Study Spironolactone 5% Topical Gel, Adapalene 0.1% Topical Gel - Acne Vulgaris | Phase 2 | Not yet recruiting | Assiut University | 40 | 2026-04-01 | 2026-03-17 |
| Topical Calcipotriol Versus Photodynamic Therapy in the Treatment of Oral Leukoplakia Calcipotriol 0.005% gel, ALA mediated PDT - Oral Leukoplakia | Phase 2 / Phase 3 | Active not recruiting | Alexandria University | 30 | 2025-07-16 | 2026-06-22 |
| Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis) Aminolevulinic acid hydrochloride 10% topical gel with Red Light - Cutaneous Squamous Cell Carcinoma | Phase 2 | Unknown | The Center for Clinical and Cosmetic Research | 20 | 2024-08-14 | 2024-08-29 |
| Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA PP405 0.05% Topical Gel, Topical Vehicle Gel - Androgenetic Alopecia | Phase 2 | Completed | Pelage Pharmaceuticals, Inc. | 78 | 2024-06-05 | 2026-10-21 |
| Evaluation of Silver Diamine Fluoride, Sodium Fluoride With Casein Phosphopeptide-Amorphous Calcium Phosphate(MI Varnish) and Dycal to Arrest Caries When Used in Indirect Pulp Capping Procedures in Children Silver Diamine Fluoride (SDF, 38%) gel, Sodium Fluoride with CPP-ACP (MI varnish), Calcium Hydroxide (CH) - Early Childhood Caries (ECC), Color Stability of Restoration | Phase 2 | Completed | University of Jazan | 90 | 2024-05-06 | 2026-10-26 |
| A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers SM-020 1% Gel - Non-Melanoma Skin Cancers | Phase 2 | Unknown | DermBiont, Inc. | 50 | 2024-03-25 | 2024-05-10 |
| Comparison Between the Effect of Aloe Vera and Benzydamine Hydrochloride Mouth Gel on Prevention of Pain and Progression of Radiation-induced Oral Mucositis Aloe vera gel, Benzydamine Hydrochloride 0.15% Oral gel, bioadhesive gel - Radiation Indused Oral Mucositis | Phase 1 / Phase 2 | Completed | Minia University | 30 | 2023-11-01 | 2025-03-06 |
| Benefits of Morphine Gel for Pain Reduction in Patients With Cancer Wounds Morphine Sulfate, Lidocaine Hcl 2% Jelly - Wounds and Injuries, Cancer Pain | Phase 2 | Unknown | Instituto Nacional de Cancer, Brazil | 106 | 2023-09-12 | 2023-09-28 |
| Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors HT-001 2% Topical Gel, HT-001 1% Topical Gel, HT-001 0.5% Topical Gel - Acneiform Eruption Due to Chemical, Xerosis Cutis | Phase 2 | Recruiting | Hoth Therapeutics, Inc. | 152 | 2023-07-19 | 2026-03-31 |
| Effect of New Topical Preparation for Treatment of Acne Vulgaris DAP-FLU ME, Adapalene .1% gel - Acne Vulgaris | Phase 2 | Unknown | Mansoura University | 20 | 2023-06-05 | 2023-06-13 |
| Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene PTW-002 10 mg/g gel, Placebo - Dystrophic Epidermolysis Bullosa | Phase 1 / Phase 2 | Unknown | Phoenicis Therapeutics | 8 | 2023-04-30 | 2023-03-31 |
| Body Massage Oil, Facial Mask, and Ready-to-drink Jelly From Snake Fruit Thai massage, Thai massage with pure coconut oil, Thai massage with oil mixed with Snake fruit extract, Control, Facial mask with Snake fruit extract, Control jelly, Jelly with Snake fruit juice - Body Massage Oil From Snake Fruit, Facial Mask From Snake Fruit | Phase 2 | Completed | Burapha University | 178 | 2023-03-20 | 2024-01-26 |
| Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 for Nasal Decolonisation of Staphylococcus Aureus Vehicle gel, 4 + 4 applications or 4 + 2 applications, LTX-109 3% gel, 4 + 4 applications, LTX-109 3% gel, 4 + 2 applications - Nasal Decolonization of Staphylococcus Aureus | Phase 2 | Completed | Pharma Holdings AS | 27 | 2022-09-19 | 2023-06-05 |
| Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk Tamoxifen, Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day, Placebo - Breast Atypical Hyperplasia, Breast Lobular Carcinoma in Situ | Phase 2 | Terminated | Mayo Clinic | 65 | 2021-07-26 | 2026-09-24 |
| Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency testosterone 1.62% gel, placebo gel - Hypogonadism, Male, Cancer | Phase 2 | Active not recruiting | Seattle Institute for Biomedical and Clinical Research | 230 | 2021-01-12 | 2026-07-06 |
| Biofreeze and the Effect on Knee Osteoarthritis Biofreeze 4 % Topical Gel, Biofreeze placebo gel - Knee Osteoarthritis | Phase 2 / Phase 3 | Completed | Memorial University of Newfoundland | 70 | 2020-11-01 | 2024-12-04 |
Showing 20 of 76. Sign in to see all of them.
Acne Vulgaris (8) · Alopecia (3) · Condylomata Acuminata (3) · Keratosis, Actinic (3) · Rosacea (3) · Varicose Ulcer (3) · Breast Neoplasms (2) · Fatigue (2) · Head and Neck Neoplasms (2) · Hypogonadism (2) · Insulin Resistance (2) · Lymphoma, T-Cell, Cutaneous (2) · Mycosis Fungoides (2) · Neoplasms (2) · Wounds and Injuries (2)
LEO Pharma (4) · MediWound Ltd (4) · Peplin (4) · University of Washington (4) · Maruho Co., Ltd. (3) · Pelage Pharmaceuticals, Inc. (3) · Allergan (2) · BioPharmX, Inc. (2) · CONRAD (2) · Galderma R&D (2) · Novan, Inc. (2) · Alexandria University (1) · American Scitech International (1) · Amirhossein Farahmand (1) · Assiut University (1)
United States (38) · Germany (5) · Australia (4) · Egypt (4) · Canada (3) · Poland (3) · Brazil (2) · Dominican Republic (2) · France (2) · Honduras (2) · Israel (2) · Netherlands (2) · Peru (2) · South Africa (2) · Sweden (2)
Stephanie T Page, MD, PhD (3) · Christina Weng (2) · Joyce Rico, MD (2) · Steven Garrett, MS, DDS (2) · William J Bremner, MD, PhD (2) · Abdias Hurtado, MD (1) · Alexa Kimball, MD, MPH (1) · Amgad El-Sayed Salem (1) · Amy Degnim, M.D. (1) · Anna Novotney-Barry (1) · AnnaMarie Daniels (1) · Axel Baltzer (1) · Brian Poligone, MD, PhD (1)
PMID 31755993, PMID 15087400, PMID 17342504, PMID 20546215, PMID 21177791, PMID 22055282, PMID 22395584, PMID 22417254, PMID 25584134, PMID 26239203, PMID 27172434, PMID 27482750, PMID 27672413, PMID 27932240, PMID 27986684, PMID 28750059, PMID 28825142, PMID 29025127, PMID 29076032, PMID 29119473, PMID 29501908, PMID 29793828, PMID 30318905, PMID 30336747, PMID 31299013, PMID 31606970, PMID 31606971, PMID 34541872, PMID 35122614, PMID 39763591, PMID 41074972, PMID 41139389, PMID 41869811, PMID 41947426
2009 (1), 2015 (1), 5UM1AI068633 (1), K23AG027238 (1), R01AG037603 (1), R01CA237607 (1)